

NOTICE: This is a translation of a notice in Japanese issued on June 25, 2024 and is made solely for the convenience of foreign shareholders. In case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

Securities code: 4536
June 25, 2024

**RESOLUTION NOTICE
OF THE 112TH ANNUAL GENERAL MEETING OF SHAREHOLDERS
OF SANTEN PHARMACEUTICAL CO., LTD.**

Dear Shareholder:

We hereby inform you of the reports and the resolutions that were made, as set forth below, at the 112th Annual General Meeting of Shareholders of the Company that was held today.

Very truly yours,

Takeshi Ito
Representative Director, President & CEO
SANTEN PHARMACEUTICAL CO., LTD.
4-20, Ofuka-cho, Kita-ku, Osaka, Japan

Reports:

1. Reports on the Business Report, Consolidated Financial Statements and Financial Statements for the 112th Business Term (April 1, 2023 to March 31, 2024)
2. Report on the Audit Reports of the Accounting Auditors and the Board of Corporate Auditors on the Consolidated Financial Statements for the 112th Business Term (April 1, 2023 to March 31, 2024)

As regards the items set forth above, the contents thereof were reported.

Resolved Items:

Proposal No. 1: Appropriation of Surplus

As to this item, the term-end dividends of profits were resolved to be JPY 17 per share as per the original proposal. Consequently, the total dividends for the annual business term, including the interim dividends previously distributed, are at JPY 33 per share.

Proposal No. 2: Appointment of Eight (8) Directors

As regards this item, Akira Kurokawa, Takeshi Ito, Rie Nakajima, Ippei Kurihara, Noboru Kotani, Tamie Minami, Masahiko Ikaga and Minoru Kikuoka were appointed as Directors as per the original proposal; each of them assumed his or her office.

Noboru Kotani, Tamie Minami, Masahiko Ikaga and Minoru Kikuoka are Outside Directors.

Proposal No. 3: Appointment of Two (2) Corporate Auditors

As regards this item, Hiroshi Isaka and Yuichiro Munakata were appointed as Corporate Auditors as per the original proposal; each of them assumed his office.

Yuichiro Munakata is an Outside Corporate Auditor.

Proposal No.4: Revision to Remuneration Limit for the Corporate Auditors

As regards this item, the limit of Corporate Auditors' remuneration was amended from "not more than 80 million *yen* per year" to "not more than 100 million *yen* per year" as per the original proposal.

ANNOUNCEMENT

At the Board of Directors' meeting, which was held after the close of this Annual General Meeting of Shareholders, Takeshi Ito was appointed as Representative Director, President and CEO. He assumed the said office.

As a result thereof, the Directors and Corporate Auditors of the Company shall be as follows:

Directors and Corporate Auditors

Akira Kurokawa	Director Chairman
Takeshi Ito	Representative Director President, Chief Executive Officer
Rie Nakajima	Director Corporate Officer Chief Operating Officer
Ippei Kurihara	Director Corporate Officer
Noboru Kotani*	Director
Tamie Minami*	Director
Masahiko Ikaga*	Director
Minoru Kikuoka*	Director
Hiroshi Isaka	Standing Corporate Auditor
Junichi Asatani**	Corporate Auditor
Yaeko Hodaka**	Corporate Auditor
Yuichiro Munakata**	Corporate Auditor

* The Outside Directors (indicated by an asterisk (*) next to their names) are Independent Officers (as set forth in Article 436-2, Paragraph 1 of the Securities Listing Regulations of the Tokyo Stock Exchange, Inc.; hereinafter, the same classification shall apply.).

** The Outside Corporate Auditors (indicated by two asterisks (**)) next to their names) are Independent Officers.

End.